A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Cytarabine (Primary) ; Decitabine (Primary) ; PCM 075 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TrovaGene
  • Most Recent Events

    • 13 Nov 2017 According to a TrovaGene media release, the company today announced the activation of its clinical trial site with Virginia Cancer Specialists and Principal Investigator Dr. Alexander Spira and the trial is being led by Hematologist Jorge Eduardo Cortes, M.D.
    • 13 Nov 2017 Status changed from not yet recruiting to recruiting, according to a TrovaGene media release.
    • 09 Oct 2017 According to a TrovaGene media release, this study was accepted by the National Library of Medicine (NLM).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top